Why the study?
Does the combination of low-dose tinzaparin and GPIIb/IIIa antagonists improve anticoagulant and antiplatelet efficacy in vitro?
Population
Human blood samples (in vitro model)
Comparison
Low-molecular-weight heparins alone or in… vs Different LMWHs compared to each other, and LMWH…
Design
Preclinical
Authors
Loading...
Should not change practice; hypothesis-generating for synergistic low-dose regimens in thromboembolic disorders.
Does the combination of low-dose tinzaparin and GPIIb/IIIa antagonists improve anticoagulant and antiplatelet efficacy in vitro?
In vitro data suggest that combining low-dose tinzaparin with low-dose GPIIb/IIIa antagonists produces synergistic anticoagulant and antiplatelet effects, which may be useful for managing thromboembolic disorders.
Shaker A. Mousa (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: